Severe Sepsis

Infectious Diseases
10
Pipeline Programs
11
Companies
12
Clinical Trials
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
2
1
5
1
Early DiscoveryClinical DevelopmentMarket

On Market (1)

Approved therapies currently available

U
MEROPENEMApproved
meropenem
Unknown Company
injection2016

Competitive Landscape

9 companies ranked by most advanced pipeline stage

Novo Nordisk
Novo NordiskBAGSVAERD DENMARK, Denmark
1 program
1
10% Hemohes®Phase 31 trial
Active Trials
NCT00135473Completed600Est. Sep 2005
GC Biopharma
GC BiopharmaKorea - Yongin
1 program
1
Immunoglobulin GPhase 31 trial
Active Trials
NCT01315496TerminatedEst. Dec 2013
E
EisaiChina - Liaoning
1 program
1
eritoran tetrasodiumPhase 31 trial
Active Trials
NCT00334828Completed2,000
Bayer
BayerLEVERKUSEN, Germany
1 program
1
meropenemPhase 31 trial
Active Trials
NCT00534287Completed600Est. Jun 2010
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
1
meropenemPhase 3
Eli Lilly and Company
Eli Lilly and CompanyINDIANAPOLIS, IN
2 programs
1
1
intensive insulin therapyPhase 2/31 trial
Drotrecogin alfaPhase 21 trial
Active Trials
NCT00386425Completed486Est. Aug 2009
NCT00159952Completed90Est. Nov 2007
InflaRx
InflaRxJENA, Germany
1 program
1
CaCP29Phase 21 trial
Active Trials
NCT02246595Completed72Est. Dec 2015
Bristol Myers Squibb
1 program
1
BMS-936559Phase 12 trials
Active Trials
NCT02576457Terminated35Est. Mar 2017
NCT01452334Withdrawn0Est. Nov 2014
BlueJay Therapeutics
BlueJay TherapeuticsCA - Redwood City
3 programs
Symphony IL-6 Cutoff Establishment Study for Patients at Risk of Severe Sepsis Due to COVID-19N/A1 trial
Symphony IL-6 Cutoff Validation Study for Patients at Risk of Severe SepsisN/A1 trial
Symphony IL-6 Study in Patients at Risk of Severe SepsisN/A1 trial
Active Trials
NCT05060250UnknownEst. Dec 2024
NCT05048927UnknownEst. Dec 2024
NCT05665153UnknownEst. Nov 2024

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
GC BiopharmaImmunoglobulin G
Bayermeropenem
Eisaieritoran tetrasodium
Novo Nordisk10% Hemohes®
Eli Lilly and Companyintensive insulin therapy
InflaRxCaCP29
Eli Lilly and CompanyDrotrecogin alfa
Bristol Myers SquibbBMS-936559
Bristol Myers SquibbBMS-936559
BlueJay TherapeuticsSymphony IL-6 Study in Patients at Risk of Severe Sepsis
BlueJay TherapeuticsSymphony IL-6 Cutoff Establishment Study for Patients at Risk of Severe Sepsis Due to COVID-19
BlueJay TherapeuticsSymphony IL-6 Cutoff Validation Study for Patients at Risk of Severe Sepsis

Clinical Trials (12)

Total enrollment: 3,883 patients across 12 trials

NCT01315496GC BiopharmaImmunoglobulin G

GCIV as an Adjuvant Therapy for Community-Acquired Severe Sepsis or Septic Shock

Start: Oct 2009Est. completion: Dec 2013
Phase 3Terminated
NCT00534287Bayermeropenem

Comparison of Two Antibiotic Regimen (Meropenem Versus Meropenem+Moxifloxacin)in the Treatment of Severe Sepsis and Septic Shock

Start: Oct 2007Est. completion: Jun 2010600 patients
Phase 3Completed
NCT00334828Eisaieritoran tetrasodium

ACCESS: A Controlled Comparison of Eritoran Tetrasodium and Placebo in Patients With Severe Sepsis

Start: Jun 20062,000 patients
Phase 3Completed
NCT00135473Novo Nordisk10% Hemohes®

Efficacy of Volume Substitution and Insulin Therapy in Severe Sepsis (VISEP Trial)

Start: Apr 2003Est. completion: Sep 2005600 patients
Phase 3Completed
NCT00159952Eli Lilly and Companyintensive insulin therapy

Effect of Hyperglycemia in PAI-1 Activity and the Relationship With Outcome in Severe Sepsis and Septic Shock

Start: Nov 2004Est. completion: Nov 200790 patients
Phase 2/3Completed
NCT02246595InflaRxCaCP29

Studying Complement Inhibition in Early, Newly Developing Septic Organ Dysfunction

Start: Apr 2014Est. completion: Dec 201572 patients
Phase 2Completed
NCT00386425Eli Lilly and CompanyDrotrecogin alfa

Evaluate Protein C Levels in Severe Sepsis Patients on Drotrecogin Alfa (Activated)

Start: Nov 2006Est. completion: Aug 2009486 patients
Phase 2Completed
NCT02576457Bristol Myers SquibbBMS-936559

Safety, Pharmacokinetics and Pharmacodynamics of BMS-936559 in Severe Sepsis

Start: Dec 2015Est. completion: Mar 201735 patients
Phase 1Terminated
NCT01452334Bristol Myers SquibbBMS-936559

Safety Study of Anti-Programmed Death-Ligand 1 in Hematologic Malignancy

Start: Nov 2011Est. completion: Nov 20140
Phase 1Withdrawn
NCT05665153BlueJay TherapeuticsSymphony IL-6 Study in Patients at Risk of Severe Sepsis

Symphony IL-6 Study in Patients at Risk of Severe Sepsis

Start: Nov 2022Est. completion: Nov 2024
N/AUnknown
NCT05060250BlueJay TherapeuticsSymphony IL-6 Cutoff Establishment Study for Patients at Risk of Severe Sepsis Due to COVID-19

Symphony IL-6 Cutoff Establishment Study for Patients at Risk of Severe Sepsis Due to COVID-19

Start: Aug 2021Est. completion: Dec 2024
N/AUnknown
NCT05048927BlueJay TherapeuticsSymphony IL-6 Cutoff Validation Study for Patients at Risk of Severe Sepsis

Symphony IL-6 Cutoff Validation Study for Patients at Risk of Severe Sepsis

Start: Aug 2021Est. completion: Dec 2024
N/AUnknown

Related Jobs in Infectious Diseases

Director, Program Management

Metaphore Biotechnologies
Somerville, MA USA
9h ago
$179K - $237K/yr

Consultor Técnico Vacinas Adulto (Brasília/DF)

GSK
BRA - Distrito Federal - Brasília
22h ago

Production Supervisor/First Line Leader

GSK
USA - North Carolina - Zebulon
22h ago

Community Engagement Account Manager - New Haven

GSK
USA - Connecticut - New Haven
22h ago

Scientist, Protein Purification

GSK
USA - Massachusetts - Cambridge
22h ago
$90K - $150K/yr

Scientist, Protein Biochemistry

GSK
USA - Massachusetts - Cambridge
22h ago
$90K - $150K/yr

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

5 late-stage (Phase 3) programs — potential near-term approvals
11 companies competing in this space

Related Indications

HIV Infections(449)COVID-19(223)Hepatitis C(191)Influenza(173)HIV(138)HIV-1-infection(115)Hepatitis C, Chronic(94)Chronic Hepatitis B(93)Chronic Hepatitis C(91)Covid19(79)